心肾贫血综合征  

Cardiorenal anemia syndrome

作　　者：叶楠[1] 程虹[1] YE Nan;CHENG Hong(Department of Nephrology,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)

机构地区：[1]首都医科大学附属北京安贞医院肾内科,北京100029

出　　处：《中国实用内科杂志》2020年第11期912-915,共4页Chinese Journal of Practical Internal Medicine

基　　金：首都卫生发展科研专项自主创新(首发2018-2-1051);北京市自然科学基金(7192050);北京市医管局“培育”计划(PX2019022)。

摘　　要：心脏与肾脏之间存在着密切的交互作用,使得心肾综合征在临床中并不少见。贫血不仅是慢性肾脏病的重要并发症之一,在心力衰竭患者中亦非常常见,因此称之为心肾贫血综合征。贫血会显著增加心力衰竭患者住院和死亡风险,并促进肾脏病进展,增加肾脏替代治疗的风险。在心肾贫血综合征的发病机制中,促红细胞生成素缺乏及铁缺乏等均起到了关键作用。因此,对于心肾贫血综合征的治疗也应重视促红细胞生成素的补充、低氧诱导因子-脯氨酰羟化酶抑制剂(HIF-PHI)及补铁治疗。目前在心肾贫血综合征的发病机制及治疗方面仍有很多问题尚未解决,需要更多的基础与临床研究提供强有力的证据。There is a close interaction between the heart and the kidney,making cardiorenal syndrome not uncommon in clinical practice.Anemia is not only one of the important complications of chronic kidney disease,but also very common in patients with heart failure,so it is called cardiorenal anemia syndrome.Anemia can significantly increase the risk of hospitalization and death in patients with heart failure,promote the progression of kidney disease,and increase the risk of renal replacement therapy.In the pathogenesis for cardiorenal anemia syndrome,erythropoietin deficiency and iron deficiency have played a key role.Therefore,the treatment of cardiorenal anemia syndrome should also focus on the supplementation of erythropoietin,hypoxia-inducible factor(HIF)prolyl hydroxylase inhibitors and iron supplementation.At present,there are still many unresolved problems in the pathogenesis and treatment of cardiorenal anemia syndrome.More basic and clinical studies are needed to provide us with strong evidence.

关 键 词：心肾贫血综合征 心肾综合征 促红细胞生成素 铁缺乏 

分 类 号：R556[医药卫生—血液循环系统疾病]